![Helen Thackray](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 1 M $ al 31/07/2026
Helen M.
Thackray is currently Director at Eupraxia Pharmaceuticals, Inc. since 2026, Member of the Institutional Review Board at Holy Cross Hospital (Maryland), and Assistant Clinical Professor at GW School of Medicine & Health Sciences since 2000.
Former positions include Independent Director at ImmunoGen, Inc. from 2021 to 2024, Chief Research & Development Officer at BioCryst Pharmaceuticals, Inc. from 2021 to 2025, Vice President-Clinical Product Development at Biosynexus, Inc. from 2001 to 2006, Chief Medical Officer & SVP-Clinical Development at GlycoMimetics, Inc. from 2012 to 2021, and Member of the Institutional Review Board at the National Center for Health Statistics.
Education includes undergraduate studies at Stanford University and a doctorate from GW School of Medicine & Health Sciences.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 13/04/2026 | 161.618 ( 0,06 % ) | 1 M $ | 31/07/2026 | |
| 13/07/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| EUPRAXIA PHARMACEUTICALS INC. | Director/Miembro de la Junta | 07/07/2026 |
Holy Cross Hospital (Maryland) | Corporate Officer/Principal | - |
Gw School of Medicine & Health Sciences
 Gw School of Medicine & Health Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/2000 |
| Empresas | Cargo | Fin |
|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 01/09/2025 |
| IMMUNOGEN, INC. | Director/Miembro de la Junta | 12/02/2024 |
GlycoMimetics, Inc.
 GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Director Técnico/Científico/I+D | 19/03/2021 |
Biosynexus, Inc.
 Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Corporate Officer/Principal | 01/01/2006 |
National Center for Health Statistics
 National Center for Health Statistics General GovernmentGovernment Provides public health statistics | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 9 |
|---|---|
BioCryst Pharmaceuticals, Inc.
 BioCryst Pharmaceuticals, Inc. BiotechnologyHealth Technology Designs and develops oral small-molecule & injectable protein therapeutics | Health Technology |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Eupraxia Pharmaceuticals, Inc.
 Eupraxia Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company focused on the development of delivered, extended-release alternatives to currently approved drugs | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biosynexus, Inc.
Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Health Technology |
GlycoMimetics, Inc.
GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Health Technology |
Holy Cross Hospital (Maryland) | Health Services |
National Center for Health Statistics
National Center for Health Statistics General GovernmentGovernment Provides public health statistics | Government |
Gw School of Medicine & Health Sciences
Gw School of Medicine & Health Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
